|Articles|July 1, 2006
- Special Issues-07-01-2006
- Volume 0
- Issue 0
Moving Biotech Products from CBER to CDER: A Work in Progress
A slow, steady process of transitioning biologicals has allayed industry concerns.
Advertisement
Articles in this issue
about 20 years ago
Analytical Instrument Qualificationabout 20 years ago
GMP and Phase I Clinical Trials: Streamlining the Critical Path?about 20 years ago
Team Effortabout 20 years ago
Rated PG: Pharmaceutical Guidance Suggestedabout 20 years ago
European Clinical Trial Regulations Undergo a Slow Revolutionabout 20 years ago
FDA Video Interview Conducted by Jill Wechsler, Washington Bureau Chiefabout 20 years ago
New Climateabout 20 years ago
2006: A Regulatory Odysseyabout 20 years ago
CDER?s Division of Post-Marketing Evaluation for Quality AssessmentAdvertisement
Advertisement
Advertisement